**Original Article**

**Short compared with standard duration of antibiotic treatment for urinary tract infection: a systematic review of randomised controlled trials**

M Michael, E M Hodson, J C Craig, S Martin, V A Moyer

See end of article for authors’ affiliations

Correspondence to:
Dr E Hodson, Centre for Kidney Research, The Children’s Hospital at Westmead, Locked Bag 4001, Westmead, NSW 2145, Australia; Elisih@chw.edu.au

Accepted 12 March 2002

U rinary tract infection (UTI) is a common condition, occurring in 2% of boys and 8% of girls by 8 years of age. Conventional treatment for UTI is 7–14 days of an antibiotic, chosen on the basis of in vitro sensitivity testing. This result is failure of bacteriuria clearance of 1–3%. The potential advantages of short course therapy include improved compliance, decreased antibiotic related side effects, diminished selection of resistant organisms, and cost savings. In adult patients single dose therapy is effective and recommended for uncomplicated UTI. In children single dose therapy has not been well accepted because of the higher prevalence of urinary tract pathology and the difficulties in excluding pyelonephritis on clinical features alone. A short course of antibiotics might be as effective as a standard course of 7–14 days and still provide the other benefits of single dose therapy.

Three previous reviews involving 8, 14, and 22 trials respectively compared single dose or short course to standard duration antibiotic treatment for lower tract UTI. Two reviews did not assess separately the efficacy of single dose and short course therapies and concluded that there was insufficient evidence to justify the use of single dose or short course antibiotic treatment for UTI in children. The third review found no difference in cure rate, based on negative urine cultures taken 4–29 days after enrolment, between short (1–4 days) and standard duration (5 days or more) therapy. However, this review included studies which used different antibiotics in the short and standard treatment duration groups. Moreover, significant heterogeneity among studies was shown, casting some doubt on the validity of combining these data in a meta-analysis. The objective of this systematic review was to summarise the evidence regarding the effects of short course (2–4 days) compared to standard duration (7–14 days) oral antibiotic treatment on the persistence of UTI at the end of treatment and on the recurrence of UTI after treatment.

**Aims:** To compare the effectiveness of short course (2–4 days) with standard duration oral antibiotic treatment (7–14 days) for urinary tract infection (UTI).

**Methods:** Meta-analysis of randomised controlled trials using a random effects model. Ten trials were eligible, involving 652 children with lower tract UTI recruited from outpatient or emergency departments. Main outcome measures were UTI at the end of treatment, UTI during follow up (recurrent UTI), and urinary pathogens resistant to the treating antibiotic.

**Results:** There was no significant difference in the frequency of positive urine cultures between the short (2–4 days) and standard duration therapy (7–14 days) for UTI in children at 0–7 days after treatment (eight studies: RR 1.06; 95% CI 0.64 to 1.76) and at 10 days to 15 months after treatment (10 studies: RR 1.01; 95% CI 0.77 to 1.33). There was no significant difference between short and standard duration therapy in the development of resistant organisms in UTI at the end of treatment (one study: RR 0.57, 95% CI 0.32 to 1.01) or in recurrent UTI (three studies: RR 0.39, 95% CI 0.12 to 1.29).

**Conclusion:** A 2–4 day course of oral antibiotics is as effective as 7–14 days in eradicating lower tract UTI in children.

**METHODS**

**Search strategies**
Randomised and quasi-randomised controlled trials were identified from MEDLINE (1966 to February 2001), EMBASE (1988 to February 2001), and the Cochrane Controlled Trials Register (Cochrane Library Issue 1, 2001) without language restriction. The optimally sensitive strategies of the Cochrane Collaboration to identify randomised controlled trials were used for MEDLINE and EMBASE searches. They were combined with subject headings and textwords for urinary tract infection and duration of treatment and limited to the paediatric age range (full details available on request). Reference lists of review articles, relevant trials, nephrology textbooks, and abstracts of scientific meetings were also searched. Two reviewers reviewed trials independently for study eligibility and extracted trial data.

**Inclusion criteria**
Randomised or quasi-randomised trials were selected if they involved children aged 3 months to 18 years with culture proven symptomatic UTI, and compared short term therapy (2–4 days) against standard therapy (7–14 days). To eliminate possible heterogeneity owing to the efficacies of different antibiotics, only studies that used the same antibiotic in both short and standard duration arms were included. The primary outcomes of interest were persisting clinical symptoms at the end of treatment, significant bacteriuria (colony counts ≥10⁵ organisms per ml of urine) at completion of therapy (0–7 days after completing treatment), and recurrent UTI after treatment (10 days or more after completing treatment). Secondary outcomes sought were compliance with medication, development of resistant organisms, costs, and side effects of therapy.

**Abbreviations:** CI, confidence interval; RCT, randomised controlled trial; RR, relative risk; UTI, urinary tract infection
<table>
<thead>
<tr>
<th>First author, Year, Country, Source</th>
<th>Patients entered</th>
<th>Patients evaluated</th>
<th>Inclusion criteria</th>
<th>Antibiotics used</th>
<th>Outcomes</th>
<th>Length of study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wientzen, 1979, USA, OPD</td>
<td>57</td>
<td>52</td>
<td>Symptomatic UTI. Children with ≥3 UTI in previous year excluded. Age 0.25–16 y. MSU*, SPA†, bag‡ samples.</td>
<td>Amoxycillin 4 days versus 10 days</td>
<td>UTI any time after treatment</td>
<td>12 months</td>
</tr>
<tr>
<td>Lohr, 1981, USA, OPD</td>
<td>55</td>
<td>49</td>
<td>Girls with symptomatic UTI. Age 2–18 y. MSU samples.</td>
<td>Nitrofurantoin 3 days versus 10 days</td>
<td>UTI 0–7 days after treatment UTI during next 6 months</td>
<td>6 months</td>
</tr>
<tr>
<td>Helin, 1981, Sweden, OPD</td>
<td>43</td>
<td>43</td>
<td>Symptomatic UTI. Age 0.25–16 y. Bag, MSU samples.</td>
<td>Trimethoprim/sulphadiazine 4 days versus 10 days</td>
<td>UTI at end of treatment UTI during next 12 months</td>
<td>12 months</td>
</tr>
<tr>
<td>Zaki, 1986, Kuwait, Not stated</td>
<td>55</td>
<td>(a) 26, (b) 29</td>
<td>Symptomatic UTI. Children with UTI in previous 6 months excluded. Age 0.5–13 y. Collection method not stated.</td>
<td>(a) Nitrofurantoin acid 3 days versus 10 days (b) TMP/SMX§ 3 days versus 10 days</td>
<td>UTI 2–3 days after treatment UTI at 1–3 months</td>
<td>3 months</td>
</tr>
<tr>
<td>Madrigal, 1988, Costa Rica, OPD</td>
<td>104</td>
<td>90</td>
<td>Symptomatic UTI. Children with recurrent UTI excluded. Age 0.25–12 y. MSU, SPA, catheter urine samples.</td>
<td>TMP/SMX 3 days versus 7 days</td>
<td>UTI 10–12 days after therapy UTI at 28–37 days</td>
<td>44 days</td>
</tr>
<tr>
<td>CSG, 1991, Denmark, OPD</td>
<td>333</td>
<td>(a) 96, (b) 78, (c) 90</td>
<td>Girls with symptomatic &amp; asymptomatic UTI. Age 1–15 y. MSU samples.</td>
<td>(a) Sulphamethizole 3 days (b) Sulphamethizole 10 days (c) Pivmecillinam 3 days</td>
<td>UTI 1–10 days after treatment UTI at 1 month or more Resistant organisms</td>
<td>80 days</td>
</tr>
<tr>
<td>Jojart, 1991, Hungary, Not stated</td>
<td>132</td>
<td>(a) 43, (b) 44</td>
<td>Symptomatic &amp; asymptomatic UTI. Children with UTI &gt;3 months earlier could be re-entered to other therapy. Age 1.5–9 y. Collection method not stated.</td>
<td>(a) Nitrofurantoin 3 days versus 14 days (b) TMP/SMX 3 days versus 10 days</td>
<td>UTI at 28–36 days after treatment</td>
<td>36 days</td>
</tr>
<tr>
<td>Gaudreault, 1992, Canada, ED</td>
<td>45</td>
<td>40</td>
<td>Symptomatic UTI. Children with UTI in previous 6 months excluded. Age 2.5–18 y. MSU samples.</td>
<td>Trimethoprim/sulphadiazine 3 days versus 10 days</td>
<td>UTI at end of treatment UTI &lt; 28 days after treatment Resistant organisms</td>
<td>38 days</td>
</tr>
<tr>
<td>Johnson, 1993, USA, OPD</td>
<td>48</td>
<td>37</td>
<td>Symptomatic UTI. Age 1–13 y. MSU, SPA, catheter samples.</td>
<td>Amoxicillin/clavulanic acid 3 days versus 10 days</td>
<td>UTI 4 days after treatment UTI 30–47 days after therapy Resistant organisms</td>
<td>33 days</td>
</tr>
<tr>
<td>Kornberg, 1994, USA, ED &amp; OPD</td>
<td>38</td>
<td>25</td>
<td>Symptomatic UTI. UTI in last 30 days excluded. Age 2–11 y. MSU, catheter samples.</td>
<td>Cefuroxime 2 days versus 10 days</td>
<td>UTI 3–5 days after treatment UTI at 1–15 months</td>
<td>15 months</td>
</tr>
</tbody>
</table>

*Mid stream urine or clean catch urine collection. †Suprapubic bladder aspiration urine collection. ‡Strap-on bag urine collection. §Trimethoprim/sulphamethoxazole. ¶Third group of study by Copenhagen Study Group not included in results. OPD, outpatient department; ED, emergency department.
Quality assessment
Two reviewers (MM and EH) assessed study quality without blinding to author or source using the criteria of the Cochrane Renal Group. Discrepancies were resolved through discussion. Quality items assessed were allocation concealment, intention to treat analysis, completeness of follow up, and blinding of participants, investigators, and outcome assessment since these may bias the underlying treatment effect.

Statistical analysis
For dichotomous outcomes the relative risks (RR) with 95% confidence intervals (CI) were calculated in RevMan for individual studies and the summary statistics were calculated using a random effects model. The random effects model takes into account between study variability as well as within study variability. A fixed effects model was also used to test the robustness of the analysis and for outliers. Heterogeneity was

### Table 2 Quality of included trials comparing short with standard duration antibiotic therapy for lower UTI

<table>
<thead>
<tr>
<th>First author</th>
<th>Allocation concealment</th>
<th>Percent lost to follow up</th>
<th>Blinding of participants and investigators</th>
<th>Blinding of outcome assessment</th>
<th>Intention to treat analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wientzen26</td>
<td>Unclear</td>
<td>9</td>
<td>Not stated</td>
<td>Not stated</td>
<td>Not stated</td>
</tr>
<tr>
<td>Loh23</td>
<td>Unclear</td>
<td>11</td>
<td>Yes</td>
<td>Not stated</td>
<td>Not stated</td>
</tr>
<tr>
<td>Helin24</td>
<td>Unclear</td>
<td>0</td>
<td>Not stated</td>
<td>Not stated</td>
<td>Not stated</td>
</tr>
<tr>
<td>Zaki25</td>
<td>Unclear</td>
<td>0</td>
<td>Not stated</td>
<td>Not stated</td>
<td>Not stated</td>
</tr>
<tr>
<td>Madrigal22</td>
<td>Unclear</td>
<td>14</td>
<td>Not stated</td>
<td>Not stated</td>
<td>Not stated</td>
</tr>
<tr>
<td>CSG21*</td>
<td>Yes</td>
<td>21</td>
<td>No</td>
<td>Not stated</td>
<td>Not stated</td>
</tr>
<tr>
<td>Jojart20</td>
<td>Unclear</td>
<td>34</td>
<td>Not stated</td>
<td>Not stated</td>
<td>Not stated</td>
</tr>
<tr>
<td>Gaudreault19</td>
<td>Unclear</td>
<td>11</td>
<td>No</td>
<td>Not stated</td>
<td>Not stated</td>
</tr>
<tr>
<td>Johnson18</td>
<td>Yes</td>
<td>23</td>
<td>No</td>
<td>Not stated</td>
<td>Not stated</td>
</tr>
<tr>
<td>Kornberg17</td>
<td>Unclear</td>
<td>16</td>
<td>Not stated</td>
<td>Not stated</td>
<td>Not stated</td>
</tr>
</tbody>
</table>

*Copenhagen Study Group of urinary tract infections in children.

Figure 1 Meta-analyses showing the summary and individual trial relative risks (95% CI) for (A) persistence of urinary tract infection at the end of treatment (8 data sets) and (B) recurrence of infection 10 days to 15 months (12 data sets) after treatment with short duration or standard duration of antibiotics. Trials are shown ordered by study weights. No heterogeneity was shown using Cochran’s Q statistic ($\chi^2$). The test statistic $Z$ indicates that there were no significant differences between short and standard durations of antibiotic therapy.
analysed using Cochran’s Q statistic with an \( \alpha \) of 0.1 used for statistical significance. Subgroup analysis was planned based on study quality, patient type (age, finding of abnormal radiological findings), and intervention (type of antibiotic used) as we postulated that the relative treatment effect could vary with these factors.

**RESULTS**

**Trial characteristics**

Of 636 titles and abstracts screened, 14 studies were identified by full text review as randomised controlled trials (RCT), which compared short course to standard duration of oral antibiotic treatment. Three studies were subsequently excluded as two\(^{11,14} \) compared different antibiotics in the short and standard duration groups, and the third\(^{15} \) compared one day treatment with 10 day treatment. A fourth trial\(^{16} \) was excluded as significantly more patients (32 of 59) with pyelonephritis were included in the seven day group compared with the three day group (11 of 58) (\( \chi^2 = 15.65, \text{df} = 1; \ p < 0.001 \)), which strongly suggested non-random allocation. Thus ten trials were included in the systematic review.\(^{17–26} \)

Table 1 summarises trial characteristics. Two trials\(^{18,19} \) had four arms and were treated as separate trials. Hence there were 12 data sets for analysis. Seven trials\(^{17,18,20–22,24–26} \) used \( \geq 10^5 \) organisms/ml to define UTI. Two trials\(^{18,21} \) used \( < 10^5 \) organisms/ml and three trials\(^{19,22,24} \) used \( < 10^6 \) organisms/ml to define UTI; the remaining studies\(^{19,20,23,25} \) did not specify this. All trials included children with previous UTI. In five trials\(^{17,18,20,21,23,25} \) urines obtained by strap on bags were excluded. Only one trial\(^{19} \) recorded persisting symptoms at the end of therapy. Two trials included children with asymptomatic UTI.\(^{18,20} \) No trial specified whether recurrent UTIs were symptomatic or asymptomatic. All trials excluded children with acute pyelonephritis (diagnosed on the basis of fever of 38°C or above with or without symptoms of loin pain, chills, vomiting, or toxic appearance) or known renal tract abnormalities. Three trials\(^{19,22,23} \) examined the occurrence of resistant organisms in children with persistent or recurrent UTI.

**Study outcomes**

As results from random and fixed effects models did not differ, only results from the random effects model are reported. After standard duration therapy, the prevalence of bacteriuria after treatment varied from 0% to 23% (median 10%, mean 14%), while that of recurrent UTI varied from 5% to 50% (median 28%, mean 24%).

There were no significant differences (fig 1) in the frequency of bacteriuria at 0–7 days after completing treatment (eight data sets; RR 1.06, 95% CI 0.64 to 1.76) or in the number of UTIs during 10 days to 15 months follow up (12 data sets; RR 1.01, 95% CI 0.77 to 1.33) between short and standard duration therapy. Analyses comparing different durations of follow up showed no differences in outcomes, so follow up data from 10 days to 15 months were combined. In the one study\(^{17} \) that reported the outcome of symptomatic UTI, symptoms persisted in three of 12 children treated for two days, but in none of 13 children treated for 10 days. However, the authors did not state at what time during or after treatment this assessment was made.

No significant differences (fig 2) between short and standard duration therapy were found in the number of children with urinary pathogens resistant to the treating antibiotic on in vitro sensitivity analysis in persistent bacteriuria (one study, RR 0.57, 95% CI 0.32 to 1.01; \( p = 0.06 \)) and in recurrent UTI (three studies; RR 0.39, 95% CI 0.12 to 1.29; \( p = 0.12 \)).
However, the summary relative risk reductions for the occurrence of resistant organisms were 43% and 61% for bacteriuria at the end of treatment and recurrent UTI respectively, suggesting a trend towards a fall in the number of children with resistant organisms following short course therapy. Three studies reported that compliance was satisfactory in both treatment groups, and one study reported that 28% were excluded from evaluation because of non-compliance. No studies evaluated the costs of the treatment regimens. Adverse effects of antibiotics were not reported in sufficient detail to allow analysis. Of the seven trials that reported on adverse effects, only two studies reported in which groups the adverse effects occurred. Overall nine children suffered adverse effects: gastrointestinal disturbances (n = 6), dizziness (n = 1), or rash (n = 2).

In subgroup analyses, relative treatment effects with short and standard duration therapy did not differ with sulphamamide containing antibiotics or with non-sulphonamide based antibiotics or between children with and without abnormal renal tracts on imaging after treatment (table 3). Subgroup analysis based on other potential effect modifiers, such as study quality and patient age, was not possible because of the limited numbers of studies available.

**Discussion**

In children with lower tract UTI there is no significant difference between short and standard duration antibiotic therapy for UTI at the end of treatment or in UTI recurrence rate 10 days to 15 months after treatment.

Although there was no significant difference in the rate of bacteriuria at the end of treatment, the wide confidence intervals of the summary estimate (RR 1.06, 95% CI 0.64 to 1.76) indicate residual imprecision in the results. Ideally a further adequately powered trial is required. About 1–3% of selected children treated for symptomatic UTI have UTI after 7–14 days of antibiotic treatment. To show a reduction in UTI after treatment from 3% to 2% or from 1% to 0.5% would require 8000 and 10 000 children, respectively, to be enrolled. Such a trial is highly improbable, so how should clinicians decide what treatment duration they should use? The relevance of the residual uncertainty to patient care depends on the risk of persistent infection with standard duration therapy. If the upper and lower limits of the 95% confidence intervals are used to define the best and worst case scenarios in 1000 children with a 1% risk of infection at the end of treatment for their first UTI, four fewer children or eight extra children would have UTI following short duration therapy compared with standard duration—a clinically unimportant difference (table 4). All trials included in this systematic review included children with recurrent UTI: such children are known to be at a higher risk of UTI at the end of treatment compared with children with their first infection. If the risk of infection following treatment is 14% with standard duration therapy, as in the included trials, then 50 fewer or 110 extra children would have UTI following short duration therapy—a difference that is clinically important. In populations with recurrent UTI and a higher risk of UTI at the end of treatment, the possible harms (delay in resolution of symptoms) of not clearing the infection would have to be weighed against the possible benefits (reduced resistance to treating antibiotics, reduced adverse effects of antibiotics, improved compliance, and reduced costs) of using a short course of therapy.

Data on the development of resistant organisms were reported in only three trials. In view of the increasing prevalence in UTI of organisms resistant to commonly used antibiotics, the possible trend towards a reduction in the

---

**Table 3** Effects of short and standard duration therapy for UTI based on antibiotics used and associated urinary tract abnormalities

<table>
<thead>
<tr>
<th>Antibiotic type</th>
<th>UTI at end of treatment</th>
<th>Recurrence of UTI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sulphonamide group†</td>
<td>0.80 (0.45 to 1.41)</td>
<td>0.98 (0.65 to 1.46)</td>
</tr>
<tr>
<td>Other antibiotics†</td>
<td>1.72 (0.64 to 3.80)</td>
<td>1.04 (0.71 to 1.52)</td>
</tr>
</tbody>
</table>

**Imaging studies:**

<table>
<thead>
<tr>
<th>Abnormality</th>
<th>UTI at end of treatment</th>
<th>Recurrence of UTI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abnormality</td>
<td>0.71 (0.38 to 1.32)</td>
<td>0.24 (0.03 to 1.67)</td>
</tr>
<tr>
<td>No abnormality</td>
<td>0.99 (0.12 to 8.56)</td>
<td>1.42 (0.09 to 21.55)</td>
</tr>
</tbody>
</table>

Results presented as relative risk and 95% CI.

†Six studies (339 patients) using sulphonamides alone or in combination with trimethoprim.

‡Intravenous pyelogram and/or micturating cystourethrogram.

§Two studies involving 154 children (60 with abnormal imaging).

¶One study involving 70 children [12 with abnormal imaging].

---

**Table 4** Estimated risk for UTI 0–7 days following short duration antibiotic therapy in 1000 children, with different risks of UTI (using the summary RR of 1.06; 95% CI of 0.64 and 1.76)

<table>
<thead>
<tr>
<th>Risk of UTI 0–7 days after standard duration therapy</th>
<th>Number with UTI after standard duration therapy</th>
<th>Extra children with UTI after short duration</th>
<th>Fewer children with UTI after short duration (best scenario)</th>
<th>Extra children with UTI after short duration (worst scenario)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1%*</td>
<td>10</td>
<td>1</td>
<td>4</td>
<td>8</td>
</tr>
<tr>
<td>3%†</td>
<td>30</td>
<td>2</td>
<td>11</td>
<td>23</td>
</tr>
<tr>
<td>14%‡</td>
<td>140</td>
<td>8</td>
<td>50</td>
<td>110</td>
</tr>
</tbody>
</table>

*Data from Craig et al.

†Data from Winberg et al.

‡Mean rate of UTI, 0–7 days after standard duration therapy from 8 data sets included in meta-analysis.

---

www.archdischild.com
number of children with resistant organisms following short duration therapy needs further study. It was not possible to determine whether short duration therapy offered any reduction in antibiotic related adverse effects. Inadequate data on compliance with medications in each treatment group were not provided in any study. No study addressed whether using short course therapy reduced costs.

There are important limitations of this systematic review because of problems with the primary studies. Some information of most relevance to clinical care was not provided in these studies. None of the trials specified the time to symptom resolution after commencement of antibiotics and whether UTI at the end of treatment or UTI recurrence were associated with clinical symptoms. Two trials enrolled both symptomatic and asymptomatic patients. Inclusion of these trials did not result in heterogeneity. It is now recommended that school aged children with asymptomatic bacteriuria should not be treated with antibiotics as they are not at increased risk of impaired renal growth or deterioration in renal function when untreated, but are at increased risk of pyelonephritis following treatment. Children with pyelonephritis or known urinary tract pathology were excluded, so no recommendations on treatment duration can be made for such children, who comprise a large proportion of excluded, so no recommendations on treatment duration can be made for such children, who comprise a large proportion of.

Combining inadequately powered trials in a meta-analysis can improve statistical power. However, this study has still not provided adequate evidence that short duration (2–4 days) is better or worse than standard duration therapy (7–14 days) in eradicating childhood UTI because of residual imprecision. For most children with first UTI, who are at low risk (1–3%) of bacteriuria at the end of treatment with standard duration treatment, this statistical imprecision is of doubtful clinical significance. Therefore, based on these data, short duration of treatment is a reasonable option for children with lower tract UTI.

ACKNOWLEDGEMENTS
The authors wish to thank Narelle Willis, Coordinator of the Cochrane Renal Group, for her help with analysis using the Review Manager software. This work has been presented in part at the Annual Scientific Meeting of the Royal Australasian College of Physicians (Sydney, 2001) and at the 12th Congress of the International Pediatric Nephrology Association (Seattle, 2001).

Authors’ affiliations
M Michael, E MH Hudson, J C Craig, S Martin, Centre for Kidney Research, The Children’s Hospital at Westmead, Sydney, Australia
V A Moyer, Center for Clinical Research and Evidence Based Medicine, The University of Texas–Houston Health Science Center, Houston, TX 77030, USA

REFERENCES

www.archdischild.com